Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas

Guido Ghilardi(Hospital of the University of Pennsylvania), Stephen J. Schuster(Hospital of the University of Pennsylvania), Rebecca Yelton(University of Pennsylvania), Levanto Schachter(Oregon Health & Science University), Shannon Gier(University of Pennsylvania), Elise A. Chong(Hospital of the University of Pennsylvania), J.D. Landsburg(Hospital of the University of Pennsylvania), Stefan K. Barta(University of Pennsylvania), Philipp Wohlfarth(Medical University of Vienna), Hatcher J. Ballard(University of Pennsylvania), Alfred L. Garfall(University of Pennsylvania), Ulrich Jäger(Medical University of Vienna), James N. Gerson(UPMC Hillman Cancer Center), Danielle Victoriano(Hospital of the University of Pennsylvania), David L. Porter(Chapman University), Staci Williamson(Oregon Health & Science University), Ellen Napier(Hospital of the University of Pennsylvania), Erin L. Weber(Hospital of the University of Pennsylvania), Jessie Myers(Oregon Health & Science University), Richard T. Maziarz(Oregon Health & Science University), A.I. Chen(Oregon Health & Science University), Raymone Pajarillo(Hospital of the University of Pennsylvania), Sunita D. Nasta(University of Pennsylvania), Alexandria Hodges Dwinal(Oregon Health & Science University), Marco Ruella(Parker Institute for Cancer Immunotherapy), Jakub Svoboda(UPMC Hillman Cancer Center)

Annals of Oncology

June 9, 2022

Cited by 95

|New England Journal of Medicine|2014|1.6k

|New England Journal of Medicine|2012|1.1k

|Journal of Clinical Oncology|2017|664

|Journal of Clinical Investigation|2016|554

|Nature Medicine|2021|523

Related Papers